Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for 2L+ R/M HNSCC patients treated with MICVO at ...

Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced ...

ATRenew Inc. (ATRenew or the Company) (NYSE: RERE), a pioneer in technology-driven recycling and trade-in solutions for ...